Abstract:Background: Chimeric antigen receptor (CAR) T cell therapy is effective in treating B-cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients' lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue, we conducted single-cell multi-omics analysis of transcriptional, clonal, and phenotypic profiles from pre- to 1-month post-infusion of CAR+ and CAR− T cells from patients who received a donor-derived 4-1BB CAR product targeting CD19. Methods: Longitudinal blood samples and infusion products were obtained from 10 individuals with large B cell lymphoma or B-cell acute lymphoblastic leukemia (CARTELL cohort in Sydney Australia1). CD45+ cells and enriched CAR+ T cells were single cell sorted for simultaneous scRNA-seq, 41 barcoded proteins (N=41) and T cell receptors, n= 115,000 cells across 21 samples. Machine learning methods were used to identify subsets of immune cells associated with clinically relevant parameters. Results: Following infusion, CAR+ and CAR− T cells showed similar differentiation profiles with clonally expanded populations across heterogeneous phenotypes, demonstrating clonal lineages and phenotypic plasticity. These findings were validated by performing the same analysis on two publicly available scRNA-seq data sets from two cohorts 2, 3 of paediatric (N=18) and adult (N=32) individual with large B cell lymphoma who received CAR19 T cells. Analysis of mass-cytometry data from our cohort and from 28 patients with B cell lymphoma treated with commercial CAR19 T cells (axi-cel)4, identified an association of CAR− and also CAR+ T cells, both expressing an 2B4− CD11b+ CD8+ phenotype, with complete remission or progressive disease at 3 and 6 months post-infusion. Finally, we report additional analysis on the immunogenomics of circulating CAR T cells in two patients who developed CAR T cell induced lymphoma and compared it with ascites and CAR-Lymphoma cells. Discussion: These results suggest that CAR+ and CAR− CD8+ T cells share a differentiation trajectory terminating in an NK-like phenotype that is associated with clinical outcome, and that non-CAR-derived signals may influence patients' immune recovery and outcomes.References 1.Bishop, D.C. et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. Blood 138, 1504-1509 (2021).2.Haradhvala, N.J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 28, 1848-1859 (2022).3.Wilson, T.L. et al. Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discov 12, 2098-2119 (2022).4.Good, Z. et al. Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy. Nat Med 28, 1860-1871 (2022). Citation Format: Raymond Y. Louie, Jerome Samir, Curtis Cai, Helen McGuire, Tim Amos, James Fergsuson, Ira Deveson, Thiruni Adikari, Martina Bonomi, David Bishop, Christopher E. Mason, Robert Balderas, Marco Ruella, Mandeep Singh, David Gottlieb, Emily Blyth, Ken Micklethwaite, Fabio Luciani. Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 882.

Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies

Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screening and single-cell sequencing

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma

Genome-wide CRISPRa screens nominate modulators of CAR T cell survival within distinct tumor cytokine milieus

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells

Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma

Analysis of Polyfunctionality for Enhanced CAR T-Cell Therapy for Hematologic Malignancies

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy

Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy

The signaling and the metabolic differences of various CAR T cell designs

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation

Engineering Improved Car T Cell Products with A Multi‐Cytokine Particle Platform for Hematologic and Solid Tumors